Semaglutide Half-Life and Pharmacokinetics
A research-use-only overview of semaglutide's reported ~7 day half-life, albumin binding, fatty-acid acylation and the pharmacokinetic basis behind it.
What is the half-life of semaglutide?
Published pharmacokinetic literature reports an elimination half-life for semaglutide of approximately 7 days, or about one week. Across subcutaneous studies the terminal half-life is commonly cited in the range of roughly 145 to 168 hours, which is why semaglutide is frequently described in the scientific literature as a once-weekly long-acting analogue. This figure is remarkably consistent between healthy subjects and subjects with type 2 diabetes, with reported geometric mean values clustering near 150 to 160 hours.
This page summarises that reported pharmacokinetic data as biochemistry education for laboratory researchers. It describes the molecular basis for the prolonged half-life. It does not provide dosing, administration or human-use information of any kind. Semaglutide discussed here is handled strictly as a research-use-only laboratory reference compound.
Molecular class and structural background
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and an analogue of the human GLP-1 hormone. Structurally it shares approximately 94 per cent homology with native human GLP-1. Native GLP-1 is an incretin peptide with a very short circulating half-life, measured in minutes, because it is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4) and cleared through renal pathways.
The semaglutide molecule was engineered with a small number of deliberate structural modifications whose purpose, in the published literature, is to extend circulation time far beyond that of the native peptide. Understanding these modifications is central to understanding why the reported half-life is measured in days rather than minutes.
- Class: GLP-1 receptor agonist, analogue of human GLP-1
- Homology: approximately 94 per cent to native human GLP-1
- Native GLP-1 half-life: minutes, due to rapid DPP-4 cleavage and renal clearance
- Semaglutide reported half-life: approximately 7 days
How the structural modifications extend the half-life
Three key engineering changes are described in the pharmacokinetic literature as the basis for the extended half-life. First, the amino acid at position 8 is substituted with alpha-aminoisobutyric acid (Aib) in place of alanine. This substitution sits at the N-terminal site where DPP-4 would normally cleave the peptide, and it confers resistance to that enzymatic degradation.
Second, a C18 fatty di-acid chain is attached at the lysine residue in position 26, connected through a hydrophilic spacer or linker. This acylation is the feature most responsible for prolonged circulation. Third, a substitution at position 34 provides a suitable attachment point for that linker without disrupting receptor binding.
Together these changes convert a peptide that would otherwise be cleared within minutes into one with a reported terminal half-life of roughly a week.
- Position 8: Aib substitution blocks DPP-4 cleavage
- Position 26: C18 fatty di-acid attached via a hydrophilic linker (acylation)
- Position 34: substitution providing a linker attachment site
Albumin binding and the fatty-acid acylation mechanism
The attached C18 fatty di-acid moiety enables reversible, high-affinity binding to serum albumin, the most abundant protein in plasma. Because serum albumin itself has a long circulating half-life, reported in the literature at roughly 19 days, a molecule that remains reversibly bound to albumin is effectively shielded from rapid filtration and degradation.
The bound fraction acts as a circulating reservoir. The reversible nature of the binding means semaglutide dissociates gradually, keeping plasma concentrations relatively stable over an extended window. This albumin-binding strategy, driven by fatty-acid acylation, is the principal pharmacokinetic reason the reported terminal half-life approaches approximately 7 days.
Absorption and Tmax for the subcutaneous route
For subcutaneous administration described in the published pharmacokinetic literature, the time to maximum plasma concentration (Tmax) is reported in the approximate range of 30 to 36 hours. This slow absorption profile is consistent with a molecule designed for prolonged, stable exposure rather than a rapid peak.
The combination of slow absorption from the subcutaneous depot and slow elimination through albumin-mediated retention produces a flat concentration-time curve relative to short-acting peptides. These figures are presented here solely as reported biochemical parameters and carry no human-use implication.
Metabolism and clearance pathways
Semaglutide is not cleared primarily as an intact molecule through a single organ. The literature describes metabolism via proteolytic cleavage of the peptide backbone combined with beta-oxidation of the fatty-acid side chain. In other words, the peptide portion is broken down by proteolysis while the attached fatty-acid chain is processed through the same oxidative pathway the body uses for ordinary fatty acids.
Because clearance is distributed across these metabolic routes rather than depending heavily on rapid renal excretion of the intact peptide, the overall rate of elimination is slow, which reinforces the long reported half-life.
- Proteolytic cleavage of the peptide backbone
- Beta-oxidation of the C18 fatty-acid side chain
- Slow overall elimination consistent with the ~7 day half-life
Time to steady state
A general pharmacokinetic principle is that a compound reaches steady state after approximately four to five elimination half-lives of repeated, consistent exposure. Applying that principle to a half-life of about one week, the published literature reports that steady-state concentrations are reached after approximately 4 to 5 weeks of once-weekly exposure.
At steady state the fluctuation between peak and trough concentrations is comparatively small, again reflecting the combined effect of slow absorption and slow, albumin-mediated elimination. These are reported population pharmacokinetic observations and are stated here only as biochemistry background.
Regulatory and anti-doping context in Australia
In Australia, semaglutide is the active ingredient in certain prescription medicines that are included on the Australian Register of Therapeutic Goods (ARTG) and regulated by the Therapeutic Goods Administration (TGA). That approved, prescription-only status applies to finished pharmaceutical products supplied under medical supervision.
Research-grade semaglutide material, including any material referenced on this site, is a separate category. It is handled as a research-use-only laboratory compound and is not for human or animal use. It is not supplied as, and should not be confused with, an approved therapeutic good.
On anti-doping status, GLP-1 receptor agonists as a class are not currently listed as prohibited substances on the World Anti-Doping Agency (WADA) Prohibited List. Prohibited List status is reviewed and updated periodically, so anyone relying on this point should confirm the current edition of the list directly. This is stated neutrally and for completeness only.
Comparing pharmacokinetic profiles
Semaglutide's reported half-life is often discussed alongside other long-acting incretin-class analogues, because the same design principle, albumin binding through fatty-acid acylation combined with DPP-4 resistance, underpins several of these molecules. Comparing their pharmacokinetic parameters is a common exercise in the research literature.
For a side-by-side look at how semaglutide's molecular profile relates to another widely studied compound in this space, the comparison overview may be useful as further biochemistry reading.
Frequently asked questions
What is the half-life of semaglutide?
Published pharmacokinetic literature reports an elimination half-life of approximately 7 days, or about one week. Subcutaneous studies commonly cite a terminal half-life in the range of roughly 145 to 168 hours.
How long does semaglutide remain in circulation?
Based on a reported half-life of about one week, a compound is generally considered substantially eliminated after roughly four to five half-lives, which corresponds to approximately 5 weeks. This is a general pharmacokinetic estimate, not human-use guidance.
Why does semaglutide have such a long half-life?
The literature attributes the long half-life mainly to a C18 fatty di-acid chain attached at position 26, which enables reversible binding to serum albumin, together with an Aib substitution at position 8 that resists DPP-4 cleavage.
How long until semaglutide reaches steady state?
Reported population pharmacokinetic data indicate steady-state concentrations are reached after approximately 4 to 5 weeks of once-weekly exposure, consistent with a half-life of about one week.
What is the Tmax of subcutaneous semaglutide?
For the subcutaneous route, the reported time to maximum plasma concentration (Tmax) is approximately 30 to 36 hours, reflecting slow absorption from the subcutaneous depot.
How is semaglutide metabolised?
The literature describes metabolism via proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty-acid side chain, rather than clearance of the intact molecule through a single route.
Is semaglutide a GLP-1 receptor agonist?
Yes. Semaglutide is a GLP-1 receptor agonist and an analogue of human GLP-1, sharing approximately 94 per cent structural homology with the native peptide.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.